Purpose: Insulin-like growth factor receptor 1 (IGF-1R) is critically involved in pancreatic
cancer pathophysiology, promoting cancer cell survival and therapeutic resistance …

Background Pancreatic ductal adenocarcinoma is a particularly challenging malignancy
characterized by poor responsiveness to conventional chemotherapy. Although this tumor …

Insulin-like growth factor-1 (IGF-1) leads via its receptor IGF-1R to the activation of the
PI3K/Akt pathway, providing antiapoptotic signals to pre-malignant and malignant cells. In …

Background Insulin-like growth factor 1 receptor (IGF1R) plays important roles in the
progression of pancreatic cancer. However, the underlying mechanism remains unclear …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers worldwide.
Although many regimens have been used for PDAC treatment, the combination of the EGF …

Background Binding of insulin-like growth factor-I (IGF-1) to its receptor (IGF-1R) initiates
downstream signals that activate PI3K/Akt/mTOR and MEK/Erk pathways, which stimulate …

4039 Background: MK-0646 binds to IGF-1R and blocks its interaction with IGF-I/II ligands,
enhances gemcitabine (G)-induced apoptosis and inhibits the MEK/Erk and the PI3 …

Previous studies in our laboratory identified that 3-deazaneplanocin A (DZNep), a
carbocyclic adenosine analog and histone methyl transferase inhibitor, suppresses TGFβ …

Background Aberrant expression and activation of the IGF-IR have been reported in a
variety of human cancers and have been associated with resistance to HER targeted …

Although gemcitabine has been approved as the first-line chemotherapeutic reagent for
pancreatic cancer, its response rate is low and average survival duration is still only …